Ariel Jassie has been appointed chief business officer and general counsel of eGenesis. Jassie most recently worked at Dermavant Sciences, where he was chief business and strategy officer. His experience also includes posts at Codiak Biosciences and Celgene (NASDAQ: [[ticker:CELG]]). Cambridge, MA-based eGenesis is researching applications of the CRISPR gene-editing technology to make pig organs suitable for transplant into humans.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
